James Chelnis, MD, FACS, is an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye. At the 2025 American ...
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous ...
Cross-industry insights and new technology are helping HCA Healthcare reduce risk, improve outcomes and lead the future of high-reliability care ...
Nigel Langley of gChem stresses excipient innovation, safer solvents, and supply chain resilience for pharma’s future in part ...
SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today ...
Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activityFinal ADAPT SC+ results show ...
Use of teduglutide appeared safe for patients with short bowel syndrome, with no increased incidence of gastrointestinal ...
Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented positive results from a Phase 1/1b study of NI-18 ...
On September 9, 2025, President Trump issued a Presidential Memorandum directing the Secretary of Health and Human Services ...
Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and ...
Q3 2025 Earnings Call Transcript October 29, 2025 Bausch Health Companies Inc. misses on earnings expectations. Reported EPS is $0.4798 EPS, expectations were $1.07. Operator: Greetings, and welcome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback